MME and hydrops fetalis: The AHA/ACC/ESC guidelines endorse a quadruple combination therapy, including an angiotensin receptor–neprilysin inhibitor (ARNI), a beta-blocker (BB), a mineralocorticoid receptor antagonist (MRA), and a sodium–glucose co-transporter 2 inhibitor (SGLT2i), for treating heart failure (HF) in adults [1,2].